InspireMD Shares Promising Findings from C-GUARDIANS U.S. IDE Trial at LINC 2024

Tuesday, 28 May 2024, 10:04
InspireMD unveils encouraging one-year follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial conducted at LINC 2024. The presentation highlights the successful outcomes and potential benefits of CGuard in cardiovascular care. The findings demonstrate the effectiveness and potential impact of the innovative device on patient health and treatment.
Investing.com
InspireMD Shares Promising Findings from C-GUARDIANS U.S. IDE Trial at LINC 2024

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from C-GUARDIANS U.S. IDE Trial at LINC 2024

InspireMD presents encouraging findings from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at LINC 2024, emphasizing the positive one-year follow-up results.

Key Points:

  • Successful Outcomes: The trial showcases promising results in patient health and treatment efficacy.
  • Impactful Device: CGuard demonstrates potential benefits in cardiovascular care and treatment.

The presentation sheds light on the effectiveness of CGuard and its implications for enhancing patient care and outcomes, marking a significant advancement in cardiovascular treatments.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe